INC424

DRUG5 trials

Conditions

Blood Coagulation DisordersBlood Platelet DisordersBone Marrow DiseasesEssential ThrombocythemiaGraft vs Host DiseaseHematologic DiseasesHemorrhagic DisordersMyelofibrosis

Phase 1

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

TerminatedNCT01730248

Novartis PharmaceuticalsMyelofibrosis

Start: 2012-12-18End: 2017-09-28Updated: 2020-12-19

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

CompletedNCT01787552

Novartis PharmaceuticalsBlood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases +7

Start: 2013-05-08End: 2018-04-10Updated: 2020-04-15

Phase 2

Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

CompletedNCT03774082

Novartis PharmaceuticalsGraft vs Host Disease

Start: 2020-05-20End: 2024-08-26Updated: 2025-12-11

Phase 3

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.

CompletedNCT01493414

Novartis PharmaceuticalsMyelofibrosis

Start: 2011-08-16End: 2017-01-26Updated: 2019-04-26

Phase 4

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

CompletedNCT01558739

Novartis PharmaceuticalsPost Essential Thrombocythaemia Myelofibrosis (PET-MF), Post Polycythaemia Myelofibrosis (PPV MF), Primary Myelofibrosis (PMF)

Start: 2012-05-31End: 2014-01-31Updated: 2015-03-03

2024-07-106 citations

S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY

HemaSphere2023-08-013 citations

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

Cancers2023-05-2211 citations

Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

Leukemia & lymphoma/Leukemia and lymphoma2020-11-1933 citations

Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study

Blood Advances2020-07-0710 citations

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

British Journal of Haematology2020-02-04104 citations

A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort

Hematology Transfusion and Cell Therapy2019-04-252 citations

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Haematologica2016-05-31155 citations

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Blood2015-12-0332 citations

Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Blood2014-12-0619 citations

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

Blood2014-12-066 citations